• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    SciSparc Ltd. - Ordinary Shares (NQ: SPRC )

    0.2244 +0.0044 (+2.00%)
    Streaming Delayed Price Updated: 10:19 AM EDT, Oct 4, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 96,286
    Open 0.2191
    Bid (Size) 0.2235 (5)
    Ask (Size) 0.2244 (2)
    Prev. Close 0.2200
    Today's Range 0.2184 - 0.2255
    52wk Range 0.2176 - 14.22
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Pharma Company Gets FDA Green Light For Next Phase Trial For Tourette Syndrome
    SciSparc secures FDA approval for Phase IIb clinical trial of SCI-110, targeting unmet needs in Tourette Syndrome, Global trial begins soon. 
    Via Benzinga
    Exposures Product Safety
    SciSparc Secures FDA Green Light to US Launch of its Pivotal Phase IIb Clinical Trial for Breakthrough Tourette Syndrome Treatment
    From SciSparc Ltd
    Via GlobeNewswire

    Performance

    YTD
    -95.59%
    -95.59%
    1 Month
    -32.81%
    -32.81%
    3 Month
    -70.16%
    -70.16%
    6 Month
    -88.13%
    -88.13%
    1 Year
    -95.61%
    -95.61%

    More News

    Read More
    SciSparc Signs Non-Binding Letter of Intent to Sell Stake in MitoCareX
    From SciSparc Ltd
    Via GlobeNewswire
    SciSparc Receives FDA Approval to Initiate Phase IIb Clinical Trial for Tourette Syndrome Treatment
    From SciSparc Ltd
    Via GlobeNewswire
    Why Is SciSparc (SPRC) Stock Up 94% Today?
    Via InvestorPlace
    SciSparc Takes Major Step Forward with IND Application submitted to the FDA for Phase IIb Clinical Trial for Tourette Syndrome Treatment
    From SciSparc Ltd
    Via GlobeNewswire
    Clearmind Medicine Files International Patent For Ibogaine Combination Therapy
    Via Benzinga
    Topics Intellectual Property
    Exposures Intellectual Property
    Why Intel Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    SciSparc-Clearmind Medicine Collaboration Announces the Publication of an International Patent Application for Pioneering Ibogaine Combination Therapy
    From SciSparc Ltd
    Via GlobeNewswire
    SciSparc Advances $1.85 million Loan to AutoMax, Following AutoMax’s Direct Import Agreement with Major Chinese Vehicle Manufacturer
    From SciSparc Ltd
    Via GlobeNewswire
    SciSparc-Clearmind Medicine Collaboration Leads to Publication of International Patent Application for Innovative MDMA-Based Combination Treatment
    From SciSparc Ltd
    Via GlobeNewswire
    Clearmind Medicine Announces Publication of International Patent Application for Innovative MDMA-Based Combination Treatment
    From Clearmind Medicine Inc.
    Via GlobeNewswire
    SciSparc-Clearmind Medicine Collaboration Leads to Publication of Application for Innovative Ketamine-Based Combination
    From SciSparc Ltd
    Via GlobeNewswire
    Why Affirm Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    SciSparc Grants Global Rights for Pain Therapy to Biotech Company in Agreement Worth up to $6 Million
    From SciSparc Ltd
    Via GlobeNewswire
    Why MIRA Pharmaceuticals Shares Are Trading Higher By Around 45%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    SciSparc Submitted IND Application to the FDA for SCI-110 Phase IIb Clinical Trial for Patients with Tourette Syndrome
    From SciSparc Ltd
    Via GlobeNewswire
    SciSparc: MitoCareX Appointed Professor Nir Peled, Seasoned Oncologist, to its Scientific Advisory Board
    From SciSparc Ltd
    Via GlobeNewswire
    Autism CBD Trial On Children Advances As Israeli Company Enrolls First Five Patients
    Via Benzinga
    SciSparc Announces Enrollment of the First Five Patients in the Clinical Trial of its Innovative SCI-210 Treatment
    From SciSparc Ltd
    Via GlobeNewswire
    Israeli Penny Stock Biotech SciSparc Outlicenses Its Cannabinoid Pain Therapy
    Via Benzinga
    Why Xperi Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    SciSparc Finalizes Exclusive Global Out-Licensing Agreement for its Pain Therapy Valued at $3 million
    From SciSparc Ltd
    Via GlobeNewswire
    Nasdaq Jumps Over 2%; Walmart Earnings Top Views
    Via Benzinga
    Dow Surges Over 500 Points; US Retail Sales Rise In July
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.